← All organizations
Highest phase reached
Phase 4
First clinical trial
Jan 1, 2001First marketed drug
Jul 25, 2000First NDA
Jul 25, 2000Last known activity
Sep 3, 2020
Acquired by Otsuka on Jan 1, 2014
Timeline
Drugs by trial phase (8 distinct, 32 trials)
Phase 4 (2 own, 0 via acquisition)
Phase 3 (3 own, 0 via acquisition)
Phase 1 (3 own, 0 via acquisition)
Indications
Approved for
Studied for
- Aggression
- Alzheimer Disease
- Amyotrophic Lateral Sclerosis
- Brain Injuries
- Brain Injuries, Traumatic
- Dementia
- Depression
- Depressive Disorder
- Depressive Disorder, Treatment-Resistant
- Diabetic Neuropathies
- Disease
- Disease Progression
- Disruptive, Impulse Control, and Conduct Disorders
- Dyskinesias
- Headache
- Major Depressive Disorder
- Migraine Disorders
- Motor Neuron Disease
- Multiple Sclerosis
- Neuralgia
- Parkinson Disease
- Psychomotor Agitation
- Schizophrenia
- Sclerosis
Marketed drugs (4)
Recent trials (35)
- NCT04464564Lead sponsorPhase 3Sep 3, 2020
- NCT04408755Lead sponsorPhase 3Jun 15, 2020
- NCT03896945Lead sponsorPhase 2/Phase 3Feb 15, 2019
- NCT03420222Lead sponsorPhase 2Jan 1, 2018
- NCT03381664Lead sponsorPhase 1Nov 28, 2017
- NCT03338920Study chairPhase 3Nov 2, 2017
- NCT03338920Lead sponsorPhase 3Nov 2, 2017
- NCT03393520Lead sponsorPhase 3Oct 13, 2017
- NCT03095066Lead sponsorPhase 2May 30, 2017
- NCT02534038Lead sponsorPhase 2Dec 1, 2015
- NCT02446132Lead sponsorPhase 3Dec 1, 2015
- NCT02496039Lead sponsorPhase 4Sep 1, 2015
- NCT02442778Lead sponsorPhase 3Sep 1, 2015
- NCT02442765Lead sponsorPhase 3Sep 1, 2015
- NCT02477670Lead sponsorPhase 2Sep 1, 2015
Details
- Founded
- Aliso Viejo, CA, US Jan 1, 1998
- First NDA
- Jul 25, 2000
- Last known activity
- Sep 3, 2020
Notes
Acquired by Otsuka 2 Dec 2014